Cargando…

Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting

SIMPLE SUMMARY: Liquid biopsy provides important information through the analysis of circulating tumour cells (CTCs) and circulating tumour-derived material, such as circulating tumour DNA (ctDNA), circulating miRNAs (cfmiRNAs) and extracellular vehicles (EVs). CTC analysis has already had an import...

Descripción completa

Detalles Bibliográficos
Autores principales: Strati, Areti, Markou, Athina, Kyriakopoulou, Evgenia, Lianidou, Evi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092977/
https://www.ncbi.nlm.nih.gov/pubmed/37046848
http://dx.doi.org/10.3390/cancers15072185
_version_ 1785023474590285824
author Strati, Areti
Markou, Athina
Kyriakopoulou, Evgenia
Lianidou, Evi
author_facet Strati, Areti
Markou, Athina
Kyriakopoulou, Evgenia
Lianidou, Evi
author_sort Strati, Areti
collection PubMed
description SIMPLE SUMMARY: Liquid biopsy provides important information through the analysis of circulating tumour cells (CTCs) and circulating tumour-derived material, such as circulating tumour DNA (ctDNA), circulating miRNAs (cfmiRNAs) and extracellular vehicles (EVs). CTC analysis has already had an important impact on the prognosis, detection of minimal residual disease (MRD), treatment selection and monitoring of cancer patients. The purpose of this review is to summarize the latest findings on the clinical significance of CTCs for the management of breast, prostate and non-small-cell lung cancer patients. ABSTRACT: Over the last decade, liquid biopsy has gained much attention as a powerful tool in personalized medicine since it enables monitoring cancer evolution and follow-up of cancer patients in real time. Through minimally invasive procedures, liquid biopsy provides important information through the analysis of circulating tumour cells (CTCs) and circulating tumour-derived material, such as circulating tumour DNA (ctDNA), circulating miRNAs (cfmiRNAs) and extracellular vehicles (EVs). CTC analysis has already had an important impact on the prognosis, detection of minimal residual disease (MRD), treatment selection and monitoring of cancer patients. Numerous clinical trials nowadays include a liquid biopsy arm. CTC analysis is now an exponentially expanding field in almost all types of solid cancers. Functional studies, mainly based on CTC-derived cell-lines and CTC-derived explants (CDx), provide important insights into the metastatic process. The purpose of this review is to summarize the latest findings on the clinical significance of CTCs for the management of cancer patients, covering the last four years. This review focuses on providing a comprehensive overview of CTC analysis in breast, prostate and non-small-cell lung cancer. The unique potential of CTC single-cell analysis for understanding metastasis biology, and the importance of quality control and standardization of methodologies used in this field, is also discussed.
format Online
Article
Text
id pubmed-10092977
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100929772023-04-13 Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting Strati, Areti Markou, Athina Kyriakopoulou, Evgenia Lianidou, Evi Cancers (Basel) Review SIMPLE SUMMARY: Liquid biopsy provides important information through the analysis of circulating tumour cells (CTCs) and circulating tumour-derived material, such as circulating tumour DNA (ctDNA), circulating miRNAs (cfmiRNAs) and extracellular vehicles (EVs). CTC analysis has already had an important impact on the prognosis, detection of minimal residual disease (MRD), treatment selection and monitoring of cancer patients. The purpose of this review is to summarize the latest findings on the clinical significance of CTCs for the management of breast, prostate and non-small-cell lung cancer patients. ABSTRACT: Over the last decade, liquid biopsy has gained much attention as a powerful tool in personalized medicine since it enables monitoring cancer evolution and follow-up of cancer patients in real time. Through minimally invasive procedures, liquid biopsy provides important information through the analysis of circulating tumour cells (CTCs) and circulating tumour-derived material, such as circulating tumour DNA (ctDNA), circulating miRNAs (cfmiRNAs) and extracellular vehicles (EVs). CTC analysis has already had an important impact on the prognosis, detection of minimal residual disease (MRD), treatment selection and monitoring of cancer patients. Numerous clinical trials nowadays include a liquid biopsy arm. CTC analysis is now an exponentially expanding field in almost all types of solid cancers. Functional studies, mainly based on CTC-derived cell-lines and CTC-derived explants (CDx), provide important insights into the metastatic process. The purpose of this review is to summarize the latest findings on the clinical significance of CTCs for the management of cancer patients, covering the last four years. This review focuses on providing a comprehensive overview of CTC analysis in breast, prostate and non-small-cell lung cancer. The unique potential of CTC single-cell analysis for understanding metastasis biology, and the importance of quality control and standardization of methodologies used in this field, is also discussed. MDPI 2023-04-06 /pmc/articles/PMC10092977/ /pubmed/37046848 http://dx.doi.org/10.3390/cancers15072185 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Strati, Areti
Markou, Athina
Kyriakopoulou, Evgenia
Lianidou, Evi
Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting
title Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting
title_full Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting
title_fullStr Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting
title_full_unstemmed Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting
title_short Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting
title_sort detection and molecular characterization of circulating tumour cells: challenges for the clinical setting
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092977/
https://www.ncbi.nlm.nih.gov/pubmed/37046848
http://dx.doi.org/10.3390/cancers15072185
work_keys_str_mv AT stratiareti detectionandmolecularcharacterizationofcirculatingtumourcellschallengesfortheclinicalsetting
AT markouathina detectionandmolecularcharacterizationofcirculatingtumourcellschallengesfortheclinicalsetting
AT kyriakopoulouevgenia detectionandmolecularcharacterizationofcirculatingtumourcellschallengesfortheclinicalsetting
AT lianidouevi detectionandmolecularcharacterizationofcirculatingtumourcellschallengesfortheclinicalsetting